Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.
NCT04969627 on ClinicalTrials.gov · last registry update 2022-04-14
Finished 4 January 2022, after enrolling 60 people. Primary outcome, as filed: Change in body weight. exenatide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Bing He
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2021-01-04
- Primary completion
- 2022-01-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in body weight
Conditions studied
Polycystic Ovary Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.